Last updated on July 2018

Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

Brief description of study

The primary objective of this study is to investigate the effect of 5 mg KHK2375 on progression free survival (PFS) when administered orally at weekly intervals in combination with exemestane in a placebo-controlled, double-blind comparative study in subjects with advanced or recurrent hormone receptor-positive breast cancer. The secondary objectives are to investigate the effect of on overall survival (OS) and the antitumor effect and to evaluate the pharmacokinetics and safety.

Clinical Study Identifier: NCT03291886

Contact Investigators or Research Sites near you

Start Over

Kyowa Hakko Kirin Co., Ltd.

Kitakyushu Municipal Medical Center
Kitakyushu, Japan